Clinical trial
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short…
NCT00125190 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00125190 |
|---|---|
| Title | Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency |
| Official title | Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Insulin-Like Growth Factor-1 Deficiency, Growth Disorders |
| Intervention type | Drug |
| Interventions | rhIGF-1 (mecasermin) for a period of 86 weeks |
| Enrollment | 45 |
| Start date | Jul 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Jul 29, 2005 |
| Last update posted | Jul 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: